Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 1/20 | 0.62 |
| ▸ | MGLL | Q99685 | 1/20 | 0.52 |
| ▸ | DGKA | P23743 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | THRB | P10828 | 1/20 | 0.51 |
| ▸ | CNR1 | P21554 | 1/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.49 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.48 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.48 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.48 |
| ▸ | PRKCA | P17252 | 1/20 | 0.48 |
| ▸ | FAAH | O00519 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20141088 | 0.96 | DNM1 (0.62) | DNM1MGLLDGKAALDH1A1MAPT | |
| SCHEMBL20139488 | 0.93 | DNM1 (0.54) | DNM1MGLLDGKAALDH1A1MAPT | |
| SCHEMBL24627685 | 0.91 | MGLL (0.59) | DNM1MGLLALDH1A1MAPTTHRB | |
| SCHEMBL20138973 | 0.90 | MGLL (0.59) | DNM1MGLLDGKAALDH1A1MAPT | |
| SCHEMBL15026930 | 0.90 | DNM1 (0.55) | DNM1MGLLDGKAEPHX2PRKCE | |
| SCHEMBL15026921 | 0.90 | DNM1 (0.55) | DNM1MGLLDGKAEPHX2PRKCE | |
| SCHEMBL22439648 | 0.89 | DNM1 (0.69) | DNM1MGLLDGKAALDH1A1MAPT | |
| SCHEMBL31179620 | 0.89 | DNM1 (0.58) | DNM1MGLLDGKAALDH1A1MAPT | |
| SCHEMBL21380037 | 0.89 | MGLL (0.59) | DNM1MGLLALDH1A1MAPTTHRB | |
| SCHEMBL15026950 | 0.89 | DNM1 (0.58) | DNM1MGLLDGKAALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140308304-A1 | LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | ALNYLAM PHARMACEUTICALS, INC. | 2014-10-16 | — | — | US | disclosed |
| US-20140308304-A1 | LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | ALNYLAM PHARMACEUTICALS, INC. | 2014-10-16 | — | — | US | disclosed |
| WO-2013086373-A1 | LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2013-06-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140308304-A1 | LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | NPC1L1, NPC1, CETP | DNM1 241/4885MGLL 127/4885DGKA 394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.